The World's Largest Single-Center Breast Cancer Program
The Department of Breast Surgery at Fudan University Shanghai Cancer Center (FUSCC) is not only China's number one breast cancer surgical program — it is one of the highest-volume breast cancer centers in the world, treating over 10,000 new breast cancer patients annually and performing more breast cancer operations each year than almost any other single institution globally. This extraordinary volume, combined with a world-class research program that has produced landmark contributions to breast cancer biology, treatment, and outcomes, makes FUSCC the definitive destination for breast cancer care in China and one of the most compelling breast cancer centers in Asia.
For international patients with breast cancer — whether seeking surgical treatment, a second opinion, access to clinical trials, or expert management of a complex or rare breast cancer subtype — FUSCC's breast surgery department offers an unparalleled combination of surgical expertise, research leadership, and multidisciplinary excellence. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination for international patients throughout their care journey at FUSCC.
About the Department
FUSCC's breast surgery department is a national key clinical specialty and the top-ranked breast cancer program in China. The department operates multiple dedicated breast surgical wards, a comprehensive breast cancer outpatient clinic, a breast cancer multidisciplinary team (MDT), a hereditary breast cancer clinic with genetic counseling, a breast imaging and biopsy service, and a dedicated breast cancer research center that is one of the most productive in Asia.
The breast cancer MDT at FUSCC is one of the most comprehensive in China, integrating breast surgery, medical oncology, radiation oncology, plastic and reconstructive surgery, pathology, radiology, nuclear medicine, genetics, and psychology to develop personalized treatment plans for every patient. Faculty members publish regularly in the world's leading oncology journals including New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, Nature Medicine, Cancer Cell, and Annals of Oncology.
Breast Cancer Subtypes Treated
- Luminal A & B (HR+/HER2-) — Breast-conserving surgery or mastectomy; sentinel lymph node biopsy; adjuvant endocrine therapy (tamoxifen, aromatase inhibitors); CDK4/6 inhibitors (abemaciclib) in high-risk node-positive disease; ovarian suppression for premenopausal patients
- HER2-Positive Breast Cancer — Neoadjuvant dual HER2 blockade (trastuzumab + pertuzumab) + chemotherapy; surgery; T-DM1 for residual disease; T-DXd for metastatic disease; tucatinib + capecitabine + trastuzumab for brain metastases
- Triple-Negative Breast Cancer (TNBC) — Neoadjuvant pembrolizumab + chemotherapy (KEYNOTE-522); surgery; capecitabine or olaparib for residual disease; sacituzumab govitecan for metastatic TNBC
- Luminal HER2-Positive — Neoadjuvant chemotherapy + dual HER2 blockade; adjuvant endocrine therapy + CDK4/6 inhibitors
- BRCA1/2-Associated Breast Cancer — Risk-reducing bilateral mastectomy; olaparib adjuvant therapy; genetic counseling
- Inflammatory Breast Cancer — Neoadjuvant systemic therapy followed by modified radical mastectomy and radiation
- Male Breast Cancer — Modified radical mastectomy and systemic therapy
- Locally Advanced Breast Cancer — Neoadjuvant chemotherapy ± targeted therapy; pathological complete response-guided adjuvant therapy
- Metastatic Breast Cancer — Comprehensive systemic therapy; CDK4/6 inhibitors; PI3K/AKT inhibitors (alpelisib, capivasertib); elacestrant for ESR1-mutated; ADCs; immunotherapy
- DCIS & High-Risk Lesions — Breast-conserving surgery or mastectomy; endocrine prevention therapy
Surgical Expertise
Breast-Conserving Surgery & Oncoplastic Techniques
FUSCC's breast surgery team performs thousands of breast-conserving operations annually, with intraoperative margin assessment to minimize re-excision rates. The department's oncoplastic program offers the full range of volume displacement and replacement techniques to achieve optimal aesthetic outcomes even for larger tumors or unfavorable locations, including therapeutic mammoplasty for large tumors and local flap reconstruction for defect filling.
Nipple-Sparing & Skin-Sparing Mastectomy
FUSCC has been at the forefront of nipple-sparing mastectomy (NSM) adoption in China, offering this procedure to eligible patients as an oncologically safe option that preserves the natural breast appearance. The department performs NSM with immediate implant-based and autologous reconstruction, with outcomes data from one of the largest NSM cohorts in China.
Breast Reconstruction
FUSCC's reconstruction program — in close collaboration with plastic surgery — offers the full range of immediate and delayed reconstruction options:
- Implant-Based Reconstruction — Direct-to-implant and tissue expander-to-implant; prepectoral and subpectoral placement; acellular dermal matrix (ADM) use
- Autologous Reconstruction — DIEP flap, latissimus dorsi flap, and TRAM flap; microsurgical free flap reconstruction
- Hybrid Reconstruction — Implant with latissimus dorsi flap coverage
- Fat Grafting — Lipofilling for contour refinement and symmetrization
Axillary Management
- Sentinel Lymph Node Biopsy (SLNB) — Dual-tracer technique; one of China's highest-volume SLNB programs
- Targeted Axillary Dissection (TAD) — For node-positive patients converting to node-negative after neoadjuvant therapy
- Axillary Lymph Node Dissection (ALND) — For persistent nodal disease
- Post-Mastectomy Lymphedema Prevention — Axillary reverse mapping (ARM) to preserve arm lymphatics during ALND
FUSCC Breast Cancer Research: World-Leading Contributions
FUSCC's breast cancer research program is one of the most productive in Asia, with landmark contributions that have shaped global breast cancer treatment:
- TNBC Molecular Subtyping — FUSCC researchers developed the FUSCC TNBC subtyping system (BL1, BL2, M, LAR) that has been adopted internationally to guide treatment selection for triple-negative breast cancer
- Neoadjuvant Therapy Optimization — Multiple landmark trials evaluating neoadjuvant chemotherapy, HER2-targeted therapy, and immunotherapy combinations
- Genomic Landscape of Chinese Breast Cancer — Large-scale genomic studies characterizing the molecular landscape of breast cancer in Chinese patients, identifying population-specific features relevant to treatment
- Liquid Biopsy — ctDNA-based monitoring for treatment response and minimal residual disease detection
Hereditary Breast Cancer Program
FUSCC's hereditary breast cancer program is one of the most comprehensive in China:
- BRCA1/2 & Multi-Gene Panel Testing — Germline testing for BRCA1/2, PALB2, CHEK2, ATM, and other breast cancer susceptibility genes
- Risk Assessment & Counseling — Lifetime risk calculation and personalized surveillance recommendations
- Risk-Reducing Surgery — Bilateral risk-reducing mastectomy and salpingo-oophorectomy for BRCA carriers
- Chemoprevention — Tamoxifen and aromatase inhibitors for high-risk women
- Family Cascade Testing — Coordination of genetic testing for at-risk family members
Clinical Trials: Access to Tomorrow's Treatments
FUSCC is one of China's most active breast cancer clinical trial centers, participating in national and international trials evaluating novel therapies across all breast cancer subtypes. For international patients, this means potential access to investigational agents not yet widely available, including:
- Novel ADCs targeting HER2, TROP2, HER3, and other antigens
- Next-generation CDK4/6 inhibitors and PI3K/AKT/mTOR pathway inhibitors
- Novel immunotherapy combinations for TNBC
- Oral SERDs and SERD combinations for HR-positive breast cancer
- PARP inhibitor combinations for BRCA-mutated breast cancer
Why International Patients Choose FUSCC Breast Surgery
- World's Largest Breast Cancer Program — Over 10,000 new patients annually; unmatched surgical volume and experience
- China's #1 Breast Cancer Center — Consistently top-ranked; the definitive destination for breast cancer care in China
- Research Leadership — Landmark contributions to TNBC subtyping, neoadjuvant therapy, and genomics; publications in NEJM, Lancet Oncology, and Nature Medicine
- Comprehensive MDT — Fully integrated multidisciplinary team covering every aspect of breast cancer care
- Clinical Trial Access — One of China's most active breast cancer trial centers with access to novel investigational therapies
- Cost-Effectiveness — World-class breast cancer care at significantly lower cost than equivalent treatment in Western countries
The CMCS Patient Journey
- Initial Inquiry — Share your breast cancer diagnosis, imaging (mammogram, ultrasound, MRI), biopsy pathology, receptor status (ER, PR, HER2, Ki67), molecular profiling, and prior treatment history with CMCS.
- Medical Record Preparation — We translate and organize your records for specialist pre-consultation review.
- Specialist Matching — We identify the most appropriate breast surgeon and oncologist based on your specific diagnosis and treatment goals.
- MDT Submission — Where appropriate, we facilitate pre-arrival case review by FUSCC's breast cancer MDT.
- Priority Scheduling — We secure a consultation and surgical slot with minimal waiting time.
- Travel & Logistics — Assistance with visa invitation letters, accommodation near FUSCC, and Shanghai airport transfers.
- Surgical Admission Support — Full coordination of pre-operative assessment, neoadjuvant therapy scheduling if required, admission, and inpatient care.
- Post-Operative Follow-Up — Pathology report translation, adjuvant therapy coordination, and remote follow-up after you return home.
Book a Consultation
If you are seeking expert breast cancer care in Shanghai — whether for surgery, neoadjuvant therapy, reconstruction, hereditary breast cancer management, or a second opinion — CMCS can arrange a specialist consultation with FUSCC's world-renowned breast surgery team.
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
0 commentaire